The Finnish Red Cross Blood Service and Baxter to partner in plasma processing
The Finnish Red Cross Blood Service and the healthcare company Baxter have entered an agreement concerning the processing of plasma. This means that some of the plasma collected in Finland will be sent to Baxter’s production plants to be processed into medicinal products. The agreement is for three years up to the end of 2014.
Plasma-derived medicinal products, or plasma products, are life-saving medicines and the need for these products is continuously increasing in Finland and other countries. The collaboration between the Blood Service and Baxter will ensure that Finnish plasma can be used effectively to treat patients with severe conditions such as immunodeficiencies, blood coagulation disorders, major haemorrhages and neurological conditions.
Plasma is a component separated from the blood that is donated by blood donors. Actual blood products, i.e. red blood cell and platelet products are manufactured and used entirely in Finland. The further processing of plasma cannot be performed in Finland. Thanks to the partnership with Baxter and others in the field of plasma processing, the Blood Service can ensure that the plasma collected in Finland is utilised fully and effectively to treat patients.
“We need reliable, high-quality partners. Baxter is an established partner that we have collaborated with also before, says Tom Krusius, the Blood Service’s Medical Director.
Baxter is a diversified healthcare company specialising in the further processing of plasma and one of the world’s leading developers and manufacturers of plasma products. Baxter works with blood service institutions in several countries to ensure the high quality and safety of plasma products.
Under the agreement, the Blood Service will sell so-called 24-hour plasma to Baxter. This term refers to plasma that must be frozen for further processing within 24 hours of collection. Annually, the amount of plasma sent to Baxter will be about 65,000 kg, which corresponds to about 85% of all plasma collected in Finland. The plasma will be sent to Baxter’s production plant in Austria for processing.
Several international manufacturers of plasma products operate in Finland, providing Finnish hospitals with plasma products for the treatment of patients. Baxter’s products are also available in Finland. The company will expand its plasma product portfolio in Finland in 2012.